



ASX RELEASE (9 JUNE 2021)

Clinical Trial Supply Agreement with Murdoch Children's Research Institute

Key Points:

- Epsilon supplying study drug for clinical study into severe behavioural problems in youth with intellectual disabilities by the Murdoch Children's Research Institute;
- Study drug is a berry flavoured 30ml CBD100 product and matching placebo;
- Supported by Victorian Department of Health with CBD Isolate received through IDT Australia for formulation of the study drug;
- Trial expected to be conducted over the next two years, with results published in a peer-reviewed publication.

Epsilon Healthcare Limited (ASX:EPN) (**Epsilon** or the **Company**) is pleased to announce that the Company is now supplying a clinical study on the treatment of severe behavioural problems in youth with intellectual disability using cannabidiol medicines (the **Trial**) being conducted by Murdoch Children's Research Institute (**MCRI**).

Trial Material Manufacturing

The Company is supplying MCRI with the study drug – a berry flavoured 30ml CBD100 product – at no cost and has developed a berry flavoured placebo for use in the study.

This trial is also supported by the Victorian Department of Health, who are providing a CBD isolate developed by IDT Australia to be used in the formulation of the study drug. This CBD Isolate was provided to the MCRI at no cost following an open tender process.

Trial Details

The Trial is a multi-centre, randomised, double-blind, placebo-controlled trial (*ClinicalTrials.gov Identifier: NCT04821856*). It is expected to occur over two years, with each participant to be involved for 10 weeks. MCRI will analyse the data independently and the results will be published in a peer-reviewed publication. In consideration for providing the study drug, the Company will receive a royalty free licence to the study data generated from the Trial. MCRI will be the sole sponsor of the Trial.

Lead Investigator, Associate Professor Daryl Efron commented:

We're pleased to have Epsilon Healthcare support this clinical study by formulating and supplying the study drug and placebo. We look forward to working with them over the coming years on this study, as well as exploring opportunities in future studies."

Chief Executive Officer of Epsilon, Jarrod White, commented:

"We see our participation in clinical trials and studies as being critical to developing the medicinal cannabis industry in Australia. We are pleased to support the Murdoch Children's Research Institute trial and appreciate the contribution from the Victorian Government which significantly reduced the cost of the Company's involvement in the project. We look forward to supporting the industry further through clinical trial and study sponsorship and supply."

For further information, please contact:



Jarrod White

Group Chief Executive Officer
e: ceo@epsilonhc.com

Sonny Didugu

Group Chief Operating Officer
e: coo@epsilonhc.com

Philip Leighfield

Joint Company Secretary
e: corporate@epsilonhc.com

ASX release authorised by the EPN Board of Directors.

Epsilon Healthcare Limited (ASX: EPN) – epsilonhelthcare.com.au

Epsilon Healthcare (ASX:EPN) is a diversified global healthcare and pharmaceuticals company. EPN owns a number of medicinal cannabis assets including the largest cannabis manufacturing facility in the Southern Hemisphere, the Tetra Health clinic group, and the Medimar Platform – an end-to-end ecommerce solution for nutraceuticals and cannabis. EPN additionally operates a turn-key cannabis cultivation solutions provider based in Vancouver, Canada.